^
Association details:
| Biomarker: | ERBB3 mutation + TMB-H |
|---|---|
| Cancer: | Bladder Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Comprehensive genomic profiling (CGP) to reveal new opportunities and challenges in muscle-invasive bladder cancer (MIBC).
Published date:
02/08/2021
Excerpt:
In the PURE-01 cohort, TMB≥10 mut/Mb was significantly associated with pCR and downstaging at univariable and multivariable analyse....TMB≥10 was associated with response to pembrolizumab, while HRR GAs with DRFS after NAC. Cases with ERBB2/3 GAs featured higher TMBs but were not associated with response to immunotherapy.
DOI:
10.1200/JCO.2021.39.6_suppl.479
